ASX Announcement $3.5 Million R&D Tax Incentive Received Melbourne, Australia; 22 October 2026: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company advancing dendrimer technology from the lab to the patient, today announces the receipt of $3.5 million under the Australian...
$3.5 Million R&D Tax Incentive Received
Filed with ASX · · 1 page · English
Release
Starpharma Holdings Limited on 6ix
In the deck
Story so far
Earlier from Starpharma
- Starpharma Investor Presentation Petalion Webinar
- Starpharma secures majority ownership of Petalion
- Trading Halt
- Change in substantial holding
- Notice of Annual General Meeting/Proxy Form
Later from Starpharma
- Quarterly Activities/Appendix 4C Cash Flow Report
- Details of Company Address
- Application for quotation of securities - SPL
- Becoming a substantial holder
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma